ANI Pharmaceuticals, Inc.
ANIP
$76.53
$0.430.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 8.45% | 7.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.45% | 7.78% | |||
| Cost of Revenue | 7.37% | 25.16% | |||
| Gross Profit | 9.20% | -1.71% | |||
| SG&A Expenses | 7.91% | -6.52% | |||
| Depreciation & Amortization | -0.08% | -2.79% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.28% | 4.38% | |||
| Operating Income | 27.53% | 51.16% | |||
| Income Before Tax | -6.87% | 221.14% | |||
| Income Tax Expenses | -44.47% | 263.51% | |||
| Earnings from Continuing Operations | 3.28% | 211.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.28% | 211.35% | |||
| EBIT | 27.53% | 51.16% | |||
| EBITDA | 13.90% | 18.66% | |||
| EPS Basic | 3.56% | 220.99% | |||
| Normalized Basic EPS | 43.29% | 49.47% | |||
| EPS Diluted | 3.42% | 213.50% | |||
| Normalized Diluted EPS | 43.06% | 45.60% | |||
| Average Basic Shares Outstanding | 3.05% | 1.21% | |||
| Average Diluted Shares Outstanding | 3.23% | 3.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -1.00% | -0.73% | |||